CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $20M, lower than 95% of all stocks globally
- FinancialsLow earnings quality
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.56BUSDvs all stocks (USD)
Revenue (TTM)
20.00MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
52-Week Change
68.79%vs all stocks
Market Capitalization
1.56BUSDvs all stocks (USD)
Enterprise Value
1.27BUSDvs all stocks (USD)
Forward P/E
-8.82xvs Biotechnology peers
Price to Sales (TTM)
77.82xvs Biotechnology peers
Price to Book (MRQ)
4.06xvs Biotechnology peers
Enterprise to Revenue
63.26xvs Biotechnology peers
Enterprise to EBITDA
-9.59xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-132.76%vs Biotechnology peers
Return on Assets (TTM)
-22.27%vs Biotechnology peers
Return on Equity (TTM)
-38.67%vs Biotechnology peers
Revenue (TTM)
20.00MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.4060USDUpdated Jul 19, 2026Gross Profit (TTM)
20.00MUSDvs all stocks (USD)
EBITDA (TTM)
-131.89MUSDvs all stocks (USD)
Net Income (TTM)
-122.54MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-121.54MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-81.70MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-142.90MUSDvs all stocks (USD)
Pre-tax Income
-131.12MUSDFY2025 · Dec 31, 2025Income Tax Expense
0.00USDFY2025 · Dec 31, 2025Net Income
-131.12MUSDFY2025 · Dec 31, 2025EBIT
-142.90MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-140.50MUSDFY2025 · Dec 31, 2025Research & Development
108.45MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
34.45MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
11.78MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-131.12MUSDFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00USDFY2025 · Dec 31, 2025Operating Cash Flow
-112.48MUSDFY2025 · Dec 31, 2025Free Cash Flow
-113.28MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
190.34MUSDFY2025 · Dec 31, 2025Income Tax Paid
0.00USDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-131.12MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
2.40MUSDFY2025 · Dec 31, 2025Stock-based Compensation
16.40MUSDFY2025 · Dec 31, 2025Other Non-cash Items
2.65MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-27.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-2.79MUSDFY2025 · Dec 31, 2025Capital Expenditures
-794.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-187.67MUSDFY2025 · Dec 31, 2025Sale of Investments
17.50MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-170.96MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Other Financing Charges
-500.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
269.77MUSDFY2025 · Dec 31, 2025Shares Outstanding
49.74MSharesUpdated Jul 19, 2026Float Shares
37.25MSharesUpdated Jul 19, 2026Shares Short
5.53MSharesUpdated Jul 19, 2026Short Ratio
7.14daysvs all stocks
Short % of Shares Outstanding
11.25%vs all stocks
% Held by Insiders
1.46%vs all stocks
% Held by Institutions
95.12%vs all stocks
Total Cash (MRQ)
352.38MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
6.37USDUpdated Jul 19, 2026Total Debt (MRQ)
61.22MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.1792xvs Biotechnology peers
Current Ratio (MRQ)
17.88xvs Biotechnology peers
Book Value per Share (MRQ)
6.93USDUpdated Jul 19, 2026Total Assets
397.13MUSDvs all stocks (USD)
Total Current Assets
349.72MUSDFY2025 · Dec 31, 2025Total Liabilities
42.16MUSDFY2025 · Dec 31, 2025Total Non-current Assets
47.41MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
19.61MUSDFY2025 · Dec 31, 2025Total Current Liabilities
22.56MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
189.25MUSDFY2025 · Dec 31, 2025Other Short-term Investments
152.67MUSDFY2025 · Dec 31, 2025Accounts Payable
1.79MUSDFY2025 · Dec 31, 2025Short-term Debt
4.79MUSDFY2025 · Dec 31, 2025Long-term Debt
18.51MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
1.09MUSDFY2025 · Dec 31, 2025Common Stock (Book)
49.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-489.55MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
354.97MUSDvs all stocks (USD)
52-Week Low
12.81USDUpdated Jul 19, 202652-Week High
53.65USDUpdated Jul 19, 202652-Week Change
68.79%vs all stocks
50-Day MA
26.78USDUpdated Jul 19, 2026200-Day MA
34.54USDUpdated Jul 19, 2026Avg 10-Day Volume
611.41KSharesUpdated Jul 19, 2026Avg 30-Day Volume
760.63KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-2.35USDUpdated Jul 19, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
Where is this company structurally exposed?
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.68
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $20M, lower than 95% of all stocks globallySignificant
Revenue (USD): 20,000,000Global P5: 30,274,777.221
Market cap is $1.56B, above the global median of $1.15BNotable
Market cap (USD): 1,556,308,739Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Green Thumb Industries Inc.
Tier 1ProductionApproval-Gated PipelineFlowRule
Enovis Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
Hualan Biological Engineering Inc.
Tier 1ProductionApproval-Gated PipelineRule
Recursion Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Arrivent Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Classys Inc.
Tier 1ProductionApproval-Gated PipelineRule
Forte Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Harbin Gloria Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sihuan Pharmaceutical Holdings Group Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Yantai Dongcheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Johnson Fine Chemical Co., Ltd.
2 interpretationsCash Elevated Relative to Current Liabilities and Total AssetsPartial Recovery After Sharp Decline
Hebei Sinopack Electronic Co., Ltd.
2 interpretationsCash Elevated Relative to Current Liabilities and Total AssetsPartial Recovery After Sharp Decline
Vanchip Tianjin Technology Co., Ltd.
2 interpretationsCash Elevated Relative to Current Liabilities and Total AssetsPartial Recovery After Sharp Decline